Company Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids.
It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.
The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005.
Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. As of February 6, 2025, Revance Therapeutics, Inc. operates as a subsidiary of Crown Laboratories, Inc.
| Country | United States |
| Founded | 1999 |
| IPO Date | Feb 6, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 597 |
| CEO | Mark Foley |
Contact Details
Address: 1222 Demonbreun Street Nashville, Delaware 37203 United States | |
| Phone | 615 724 7755 |
| Website | revance.com |
Stock Details
| Ticker Symbol | RVNC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479290 |
| CUSIP Number | 761330109 |
| ISIN Number | US7613301099 |
| Employer ID | 77-0551645 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark J. Foley | Chief Executive Officer and Director |
| Tobin C. Schilke | Chief Financial Officer and Principal Accounting Officer |
| Dwight O. Moxie J.D. | Chief Legal Officer and General Counsel |
| Amie Krause | Chief People Officer |
| Dr. Conor Gallagher | Head of Medical Affairs and Aesthetics |
| Dr. David A. Hollander M.B.A., M.D. | Chief Medical Officer of Global Therapeutics Franchise Lead |
| Erica Jordan | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 6, 2025 | SCHEDULE 13G | Filing |
| Feb 6, 2025 | 25-NSE | Filing |
| Feb 6, 2025 | 8-K | Current Report |
| Feb 5, 2025 | SC 14D9/A | Filing |
| Feb 5, 2025 | SC TO-T/A | Filing |
| Jan 31, 2025 | SC TO-T/A | Filing |
| Jan 31, 2025 | SC 14D9/A | Filing |
| Jan 30, 2025 | SCHEDULE 13D/A | Filing |
| Jan 21, 2025 | SC 14D9/A | Filing |
| Jan 21, 2025 | SC TO-T/A | Filing |